Mandate

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

July 24, 2025

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).

Vida is a global supplier of processed products from Swedish forests. The Vida group has approximately 1,600 employees and sales of SEK 12 billion and conducts operations at 24 production facilities, including 12 sawmills. AB Karl Hedin Sågverk has three sawmills in Sweden and a well-established raw materials organisation in Bergslagen. The company has approximately 220 full-time employees and sales of SEK 1.8 billion. Following the acquisition, AB Karl Hedin Sågverk will continue to operate under its current name and trademark with Fredrik Marnefeldt as CEO.

Together Vida and AB Karl Hedin Sågverk will have a turnover of approximately SEK 14 billion, 1,800 employees and a sawmill production of 3.3 million cubic metres.

The transaction is subject to regulatory approvals.

Vinge’s team consisted mainly of Jonas Johansson, Johan Winnerblad, Egil Svensson and Olof Löfvenberg.

Read more in AB Karl Hedin's press release 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025